SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Repros Therapeutics Inc.' Proellex®-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids